On the stock market since 2019, it operates in the world of health and science. It has 128 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 58% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 33% below its peak. The market has trimmed its expectations for the company.
Sales run at $521K a year. A small number, but proof the product has real buyers.
There is $704.3M in the vault; even if every debt were paid off, $702.0M would remain.
Over the last 12 months, company executives reported 39 buys and 28 sells. Management buying with its own money is usually read as a good sign.
A loss of $152.1M against $521K in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, MORF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MORF is a high-risk stock — not yet profitable, and its future rides on its product catching on.